Andrew Goodman

Professor Andrew Goodman acquired his PhD in Microbiology at Harvard University in 2006, following which he did his postdoctoral study at Washington University School of Medicine from 2006 to 2010. His research focuses on the gut microbiome. Goodman’s laboratory created new strategies for the study of the microbiome, as they combine the insertion sequencing (INSeq) technique and transposon mutagenesis with high-throughput sequencing, as an effective tool to investigate fitness determinants of a human symbiont in a mammalian host. Goodman considers a great importance of the gut microbiome ecologies to host health. The overall goal of the Goodman lab is to dissect the mechanisms that commensal gut microbes use to compete, cooperate, and antagonize each other in the gut and to explore how microbiome variation impacts our response to external perturbations, including pathogenic infection and medical drugs.

Lab Information

Goodman Lab

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Microbiome 0 Genetic Engineering 0 Genomics 0 Gut 0 Bacteria 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (1)


This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More


This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More


The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


  1. Tenembaum S, Yeh EA; Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC). Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis. Front Pediatr. 2020;8:339. Published 2020 Jun 25. doi:10.3389/fped.2020.00339

  2. Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613-1626. doi:10.1016/S0140-6736(20)30932-6

  3. Gallaher JR, Dixon A, Cockcroft A, et al. Large volume transfusion with whole blood is safe compared with component therapy. J Trauma Acute Care Surg. 2020;89(1):238-245. doi:10.1097/TA.0000000000002687

  4. Cain AK, Barquist L, Goodman AL, Paulsen IT, Parkhill J, van Opijnen T. A decade of advances in transposon-insertion sequencing [published online ahead of print, 2020 Jun 12]. Nat Rev Genet. 2020;1-15. doi:10.1038/s41576-020-0244-x

  5. Zilberman-Rudenko J, Behrens B, McCully B, et al. Use of Bilobed Partial Resuscitative Endovascular Balloon Occlusion of the Aorta (pREBOA) is Logistically Superior in Prolonged Management of a Highly Lethal Aortic Injury [published online ahead of print, 2020 May 26]. J Trauma Acute Care Surg. 2020;10.1097/TA.0000000000002797.


This guy hasn’t plasmids anything yet.

Hot plasmids


This guy has no following anyone.

Popular Cloud Scientists

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2025 MolecularCloud